Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306254299> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4306254299 abstract "Abstract Background Despite statin treatment, patients with elevated low-density lipoprotein cholesterol (LDL-C) levels remain at high risk for acute cardiovascular events. Ezetimibe, evolocumab, and alirocumab were consequently developed to reduce the risk of recurrent ischemic events in patients with established cardiovascular diseases by 6%, 15%, and 15%, respectively. However, these novel treatments must demonstrate both clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers. Objective To assess the cost-effectiveness of statins in combination with ezetimibe, evolocumab, and alirocumab for secondary cardiovascular prevention from the perspective of England's National Health Service (NHS). Methods The incidence of major adverse cardiovascular events, including, myocardial infarction, stroke, angina, and coronary revascularization, was simulated with a Markov cohort model. The model was populated with transition probabilities and hazard ratios derived from cardiovascular outcome trials for statin combinations with ezetimibe (IMPROVE-IT), evolocumab (FOURIER), and alirocumab (ODYSSEY). Costs and utilities were retrieved from previous literature. Principle outcomes of interest were the incremental cost-effectiveness ratios (ICER) per quality-adjusted life year (QALY) gained in 2021 Great Britain Pounds (£). Univariate, scenario, willingness-to-pay, and probabilistic sensitivity analyses were conducted to assess the robustness of results. Results For secondary cardiovascular prevention, ezetimibe in combination with statins increased QALYs gained by 0.60 at cost reductions of −£2,529 (ICER: −4,231 £/QALY) per patients compared to statin monotherapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provided incremental QALYs of 0.53 and 0.86 at costs of £45,279 and £46,375 for evolocumab (ICER: 75,283 £/QALY) and alirocumab (ICER: 40,708 £/QALY), respectively. At the NHS' willingness-to-pay threshold of 30,000 £/QALY, there is 100% probability for ezetimibe and 0% probability for PCSK9 inhibitors to be cost-effective in secondary prevention. Results remained robust under univariate, scenario, and probabilistic sensitivity analyses. Conclusions Ezetimibe is cost-effective for secondary cardiovascular prevention at an annual price of £346 in the UK. For PCSK9 inhibitors, discounts of −37% to −53% on alirocumab's (£4,412) and evolocumab's (£4,467) prices are necessary to achieve cost-effectiveness. Funding Acknowledgement Type of funding sources: None." @default.
- W4306254299 created "2022-10-15" @default.
- W4306254299 creator A5000839870 @default.
- W4306254299 creator A5018170393 @default.
- W4306254299 creator A5033869278 @default.
- W4306254299 creator A5074524521 @default.
- W4306254299 date "2022-10-01" @default.
- W4306254299 modified "2023-10-17" @default.
- W4306254299 title "Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab" @default.
- W4306254299 doi "https://doi.org/10.1093/eurheartj/ehac544.2367" @default.
- W4306254299 hasPublicationYear "2022" @default.
- W4306254299 type Work @default.
- W4306254299 citedByCount "1" @default.
- W4306254299 countsByYear W43062542992023 @default.
- W4306254299 crossrefType "journal-article" @default.
- W4306254299 hasAuthorship W4306254299A5000839870 @default.
- W4306254299 hasAuthorship W4306254299A5018170393 @default.
- W4306254299 hasAuthorship W4306254299A5033869278 @default.
- W4306254299 hasAuthorship W4306254299A5074524521 @default.
- W4306254299 hasBestOaLocation W43062542991 @default.
- W4306254299 hasConcept C112930515 @default.
- W4306254299 hasConcept C126322002 @default.
- W4306254299 hasConcept C2776839432 @default.
- W4306254299 hasConcept C2778114629 @default.
- W4306254299 hasConcept C2778163477 @default.
- W4306254299 hasConcept C2778657065 @default.
- W4306254299 hasConcept C2780072125 @default.
- W4306254299 hasConcept C2780745583 @default.
- W4306254299 hasConcept C2780902209 @default.
- W4306254299 hasConcept C2780948078 @default.
- W4306254299 hasConcept C3019080777 @default.
- W4306254299 hasConcept C43554185 @default.
- W4306254299 hasConcept C62746215 @default.
- W4306254299 hasConcept C64332521 @default.
- W4306254299 hasConcept C71924100 @default.
- W4306254299 hasConceptScore W4306254299C112930515 @default.
- W4306254299 hasConceptScore W4306254299C126322002 @default.
- W4306254299 hasConceptScore W4306254299C2776839432 @default.
- W4306254299 hasConceptScore W4306254299C2778114629 @default.
- W4306254299 hasConceptScore W4306254299C2778163477 @default.
- W4306254299 hasConceptScore W4306254299C2778657065 @default.
- W4306254299 hasConceptScore W4306254299C2780072125 @default.
- W4306254299 hasConceptScore W4306254299C2780745583 @default.
- W4306254299 hasConceptScore W4306254299C2780902209 @default.
- W4306254299 hasConceptScore W4306254299C2780948078 @default.
- W4306254299 hasConceptScore W4306254299C3019080777 @default.
- W4306254299 hasConceptScore W4306254299C43554185 @default.
- W4306254299 hasConceptScore W4306254299C62746215 @default.
- W4306254299 hasConceptScore W4306254299C64332521 @default.
- W4306254299 hasConceptScore W4306254299C71924100 @default.
- W4306254299 hasIssue "Supplement_2" @default.
- W4306254299 hasLocation W43062542991 @default.
- W4306254299 hasOpenAccess W4306254299 @default.
- W4306254299 hasPrimaryLocation W43062542991 @default.
- W4306254299 hasRelatedWork W2626674165 @default.
- W4306254299 hasRelatedWork W2911702236 @default.
- W4306254299 hasRelatedWork W2922111129 @default.
- W4306254299 hasRelatedWork W2979834087 @default.
- W4306254299 hasRelatedWork W3103075301 @default.
- W4306254299 hasRelatedWork W4245825619 @default.
- W4306254299 hasRelatedWork W4306247171 @default.
- W4306254299 hasRelatedWork W4306254299 @default.
- W4306254299 hasRelatedWork W4366606415 @default.
- W4306254299 hasRelatedWork W2169633553 @default.
- W4306254299 hasVolume "43" @default.
- W4306254299 isParatext "false" @default.
- W4306254299 isRetracted "false" @default.
- W4306254299 workType "article" @default.